D. Nikolopoulos

发表

mins TAP TAP DCN Accuracy Training phase Prediction phase Figure 1 : Schematic TAPAS workflow

C. Bekas, G. Mariani, F. Scheidegger, 2018 .

Tailored treatment strategies and future directions in systemic lupus erythematosus

D. Nikolopoulos, L. Fotis, O. Gioti, 2022, Rheumatology International.

Suspected systemic rheumatic diseases in patients presenting with cytopenias.

D. Nikolopoulos, G. Bertsias, C. Adamichou, 2019, Best practice & research. Clinical rheumatology.

Cardiovascular Disease in Systemic Lupus Erythematosus: recent data on epidemiology, risk factors and prevention.

D. Nikolopoulos, I. Parodis, G. Bertsias, 2019, Current vascular pharmacology.

Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ‘Attikon’ cohort

D. Nikolopoulos, D. Boumpas, A. Fanouriakis, 2020, Lupus.

In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment

D. Nikolopoulos, D. Boumpas, A. Bortoluzzi, 2019, Annals of the rheumatic diseases.

Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus

S. Giannouli, P. Pavlidis, D. Nikolopoulos, 2019, Annals of the rheumatic diseases.

Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients

M. Aringer, E. Svenungsson, F. Houssiau, 2021, Annals of the Rheumatic Diseases.

Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the “Attikon” Lupus Cohort

M. Papathanasiou, D. Nikolopoulos, D. Boumpas, 2022, Frontiers in Neurology.

Using open source software for the supervision and management of the water resources system of Athens

Demetris Koutsoyiannis, A. Efstratiadis, N. Mamassis, 2012 .

Tailored treatment strategies and future directions in systemic lupus erythematosus

D. Nikolopoulos, L. Fotis, O. Gioti, 2022, Rheumatology International.

Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis

E. Frangou, E. Dermitzakis, E. Athanasiadis, 2022, Annals of the Rheumatic Diseases.

ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus

D. Nikolopoulos, D. Boumpas, P. Verginis, 2022, Science advances.

Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus

D. Nikolopoulos, D. Boumpas, A. Bortoluzzi, 2021, Annals of the Rheumatic Diseases.

Microglia activation in the presence of intact blood–brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus

D. Nikolopoulos, D. Boumpas, G. Bertsias, 2023, Annals of the Rheumatic Diseases.

Update on the pathogenesis of central nervous system lupus.

D. Nikolopoulos, D. Boumpas, A. Fanouriakis, 2019, Current opinion in rheumatology.

Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management

D. Nikolopoulos, D. Boumpas, A. Fanouriakis, 2019, Mediterranean journal of rheumatology.

Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study

A. Elezoglou, D. Nikolopoulos, D. Boumpas, 2023, Frontiers in Immunology.

Demyelination with autoimmune features (DAF): A distinct clinical entity? Results from a longitudinal cohort.

M. Papathanasiou, D. Nikolopoulos, D. Boumpas, 2021, Rheumatology.

Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease

D. Nikolopoulos, D. Boumpas, A. Fanouriakis, 2020, Lupus science & medicine.

Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives

D. Nikolopoulos, G. Bertsias, A. Fanouriakis, 2021, Expert review of clinical immunology.

First diagnosis of systemic lupus erythematosus in hospitalized patients: Clinical phenotypes and pitfalls for the non-specialist.

D. Nikolopoulos, D. Boumpas, G. Bertsias, 2021, The American journal of medicine.

The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis

D. Nikolopoulos, I. Bellos, I. Michelakis, 2020, Clinical Rheumatology.

Restoration of aberrant gene expression of monocytes in systemic lupus erythematosus via a combined transcriptome-reversal and network-based drug repurposing strategy

E. Frangou, D. Nikolopoulos, D. Boumpas, 2023, BMC Genomics.

Relapses are common in severe hematologic systemic lupus erythematosus and may be prevented by early institution of immunosuppressive agents: Α real-life single-center study

D. Nikolopoulos, D. Boumpas, A. Fanouriakis, 2022, Lupus.

Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study.

L. Rönnblom, A. Bengtsson, I. Gunnarsson, 2020, Seminars in arthritis and rheumatism.

A network-based approach reveals long non-coding RNAs associated with disease activity in lupus nephritis: key pathways for flare and potential biomarkers to be used as liquid biopsies

D. Nikolopoulos, D. Boumpas, A. Banos, 2023, Frontiers in immunology.

Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study.

D. Nikolopoulos, D. Boumpas, K. Boki, 2021, Clinical and Experimental Rheumatology.

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition

D. Nikolopoulos, I. Parodis, 2023, Frontiers in Medicine.

Advances in the pharmacological management of systemic lupus erythematosus

D. Nikolopoulos, Alexander Tsoi, Ioannis Parodis, 2024, Expert opinion on pharmacotherapy.

Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events

D. Nikolopoulos, G. Bertsias, A. Fanouriakis, 2024, Annals of the rheumatic diseases.

Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis

V. Devauchelle-Pensec, G. Barturen, S. Jousse-Joulin, 2024, Kidney international reports.

Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials.

D. Nikolopoulos, J. Lindblom, Ioannis Parodis, 2024, Rheumatology international.

Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus

D. Nikolopoulos, R. Depascale, Ioannis Parodis, 2024, Mediterranean journal of rheumatology.